Picture [iito] Made Without Love 650x80px
Document › Details

Cell and Gene Therapy Catapult, The. (10/3/17). "Press Release: Cell and Gene Therapy Catapult Enters into Partnership with Forum for Innovative Regenerative Medicine".

Region Region Japan
Organisations Organisation Cell and Gene Therapy Catapult (CGT Catapult) (GB)
  Group United Kingdom (GB) (govt)
  Organisation 2 Forum for Innovative Regenerative Medicine (FIRM) (JP)
Products Product cell therapy
  Product 2 business development (state/region)
Index term Index term Forum for Innovative Regenerative Medicine (JP)–United Kingdom (govt): cell therapy, 201710– collab MoU signed by FIRM + CGT Catapult
Persons Person Thompson, Keith (United Kingdom (govt) 201204– CEO of Cell Therapy Catapult before SNBTS)
  Person 2 Toda, Yuzo (Fujifilm 200905 General Manager Life Science Products Divison + FIRM 2017)

Memorandum of Understanding between CGT Catapult and FIRM provides prelude to cooperative relationship between UK and Japan cell and gene therapy areas

The Cell and Gene Therapy Catapult (CGT Catapult) today announced it has signed a Memorandum of Understanding (MoU) with the Forum for Innovative Regenerative Medicine (FIRM), Japan. This agreement demonstrates the shared ambition between the CGT Catapult and FIRM, an incorporated association focused on accelerating research and commercialisation of regenerative medicine, and aims to explore the possibility of a cooperative relationship to raise the international reach of the respective organisations.

Through this collaboration, FIRM and the CGT Catapult aim to advance their individual and common missions by connecting major industry players in Japan and the UK and sharing information regarding regenerative medicine technologies, policies, and legal issues. Through the combined efforts outlined within the memorandum, FIRM and the CGT Catapult hope to continue to increase the profile and standing of their countries in the cell and gene therapy space, advancing both organisations places at the forefront of cell and gene therapy research globally.

“We are pleased to announce this memorandum of understanding. The agreement with FIRM will enable us to boost the reach and profile of the Cell and Gene Therapy Catapult in Japan and ultimately develop stronger links between industry in both countries.”
Keith Thompson, CEO, Cell and Gene Therapy Catapult

FIRM works closely with the Japanese government and academia to establish a social structure to safely and continuously deliver regenerative medicinal products. More than 230 Japanese companies make up FIRM’s membership, with organisations from various fields such as pharmaceuticals, biotechnology, manufacturing, transportation, and insurance offering diverse expertise to support the research, development and delivery of regenerative medicine. Through policy, commercialisation and network support, FIRM promotes the practical use of technological innovation.

“The partnership between the Cell and Gene Therapy Catapult and FIRM will clearly promote the collaboration of industries between the UK and Japan, and accelerate the development of regenerative and cellular medicine products not only in both countries but worldwide.”
Yuzo Toda, Chairman, FIRM

“This marks yet another relationship with an important major international institution in the cell and gene therapy space, indicating that the Cell and Gene Therapy Catapult is continuing towards its goal of becoming a global hub of expertise in this burgeoning area of Life Sciences.”
Keith Thompson, CEO, Cell and Gene Therapy Catapult

Record changed: 2019-06-09


Picture [iito] Plain Stupid Simple 650x80px

More documents for United Kingdom (GB) (govt)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top